Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gamal Shiha

Showing results (41-50 of 77) with videos related to

Pageof 8
Sort By:
World Journal of Gastrointestinal Endoscopy|November 19, 2025
Subtype-specific risk factors for gastric adenomas and independent predictors of recurrence after endoscopic resectionNada El-Domiaty, Frédéric Beuvon, Marine Carpentier-Pourquier, et al.
Egyptian Liver Journal|November 15, 2021
Management of liver disease patients in different clinical situations during COVID-19 pandemicSamy Zaky, Mohamed Alboraie, Mohamed El Badry, et al.
Journal of Medical Virology|June 15, 2018
Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II studyImam Waked, Gamal Esmat, Rabab Fouad, et al.
Obesity Surgery|November 28, 2025
Prevalence and Predictors of Hepatic Steatosis in Patients Undergoing Sleeve Gastrectomy: A Biopsy-proven StudyRiham Soliman, Ahmed Helmy, Nabiel Mikhail, et al.
Journal of Hepatology|May 5, 2015
Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4Wahid Doss, Gamal Shiha, Mohamed Hassany, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trialImam Waked, Gamal Shiha, Roula B Qaqish, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 10, 2006
Consensus on extra-hepatic portal vein obstructionShiv Kumar Sarin, Jose D Sollano, Yogesh Kumar Chawla, et al.
Therapeutic Advances in Endocrinology and Metabolism|December 22, 2025
The burden of metabolic diseases in the Arab region, 1990-2021Ziyan Pan, Yasser Fouad, Faisal Abaalkhail, et al.
Odontology|September 15, 2025
Periodontitis and Metabolic Dysfunction-Associated Steatotic Liver Disease: emphasizing the clinical interplay between hepatologists and dentistsNasser Mousa, Alaa Elmetwalli, Ahmed Abdel-Razik, et al.
Gut|April 19, 2018
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in EgyptGamal Shiha, Gamal Esmat, Mohamed Hassany, et al.
Pageof 8

Showing results (41-50 of 77) with videos related to

Sort By:
Pageof 8
World Journal of Gastrointestinal Endoscopy|November 19, 2025
Subtype-specific risk factors for gastric adenomas and independent predictors of recurrence after endoscopic resectionNada El-Domiaty, Frédéric Beuvon, Marine Carpentier-Pourquier, et al.
Egyptian Liver Journal|November 15, 2021
Management of liver disease patients in different clinical situations during COVID-19 pandemicSamy Zaky, Mohamed Alboraie, Mohamed El Badry, et al.
Journal of Medical Virology|June 15, 2018
Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II studyImam Waked, Gamal Esmat, Rabab Fouad, et al.
Obesity Surgery|November 28, 2025
Prevalence and Predictors of Hepatic Steatosis in Patients Undergoing Sleeve Gastrectomy: A Biopsy-proven StudyRiham Soliman, Ahmed Helmy, Nabiel Mikhail, et al.
Journal of Hepatology|May 5, 2015
Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4Wahid Doss, Gamal Shiha, Mohamed Hassany, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trialImam Waked, Gamal Shiha, Roula B Qaqish, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 10, 2006
Consensus on extra-hepatic portal vein obstructionShiv Kumar Sarin, Jose D Sollano, Yogesh Kumar Chawla, et al.
Therapeutic Advances in Endocrinology and Metabolism|December 22, 2025
The burden of metabolic diseases in the Arab region, 1990-2021Ziyan Pan, Yasser Fouad, Faisal Abaalkhail, et al.
Odontology|September 15, 2025
Periodontitis and Metabolic Dysfunction-Associated Steatotic Liver Disease: emphasizing the clinical interplay between hepatologists and dentistsNasser Mousa, Alaa Elmetwalli, Ahmed Abdel-Razik, et al.
Gut|April 19, 2018
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in EgyptGamal Shiha, Gamal Esmat, Mohamed Hassany, et al.
Pageof 8